IP20-10: Final results from a phase I clinical trial of intravesical therapy with autologous tumor infiltrating lymphocytes (TIL) in BCG-exposed non-muscle invasive bladder cancer

IP20-10: Final results from a phase I clinical trial of intravesical therapy with autologous tumor infiltrating lymphocytes (TIL) in BCG-exposed non-muscle invasive bladder cancer

Friday, May 15, 2026 3:30 PM to 5:30 PM · 1 hr. 59 min. (America/New_York)
146A
Abstract

Log in

See all the content and easy-to-use features by logging in or registering!